{
  "_comment": "MEDKITT LANDING PAGE CONFIG - Edit this file to update your credentials and demo content",
  "_instructions": "After editing, run: cd ~/Desktop/medkitt && git add docs/config/ && git commit -m 'Update landing page config' && git push",
  
  "credentials": {
    "name": "Dr. Andy Kitlowski",
    "credentials": ["MD", "FACEP"],
    "title": "Emergency Medicine Physician",
    "role": "Co-Founder & Clinical Lead",
    "bio": "Board-certified emergency physician with expertise in clinical decision support and emergency medicine informatics. Passionate about leveraging AI to improve patient care and reduce cognitive load for clinicians.",
    "photoUrl": null,
    "certifications": [
      {
        "abbreviation": "ABEM",
        "name": "American Board of Emergency Medicine",
        "organization": "American Board of Medical Specialties",
        "year": 2018
      },
      {
        "abbreviation": "FACEP",
        "name": "Fellow of American College of Emergency Physicians",
        "organization": "ACEP",
        "year": 2020
      },
      {
        "abbreviation": "ACLS",
        "name": "Advanced Cardiac Life Support",
        "organization": "AHA"
      },
      {
        "abbreviation": "PALS",
        "name": "Pediatric Advanced Life Support",
        "organization": "AHA"
      }
    ],
    "affiliations": [
      {
        "name": "Dell Seton Medical Center",
        "location": "Austin, TX",
        "type": "Level 1 Trauma Center"
      },
      {
        "name": "UT Austin Dell Medical School",
        "location": "Austin, TX",
        "type": "Academic Affiliation"
      }
    ]
  },

  "demoWidget": {
    "enabled": true,
    "title": "Try It Now",
    "subtitle": "Select a clinical scenario and ask questions just like you would in a real consult. No signup required.",
    "scenarios": [
      {
        "id": "neurosyphilis",
        "title": "Neurosyphilis Workup",
        "description": "Suspected neurosyphilis in a patient with reactive syphilis serology and neurologic symptoms",
        "patientInfo": {
          "age": 42,
          "sex": "Male",
          "chiefComplaint": "Headache and vision changes",
          "vitals": {
            "bp": "138/84",
            "hr": 88,
            "rr": 16,
            "spo2": 98,
            "temp": 37.2
          },
          "history": ["Reactive RPR 1:128", "Confusion x 1 week", "Bilateral vision changes"]
        },
        "openingMessage": "I see a 42yo male with reactive syphilis serology (RPR 1:128), confusion, and bilateral vision changes. The key question: does this patient need a lumbar puncture to evaluate for neurosyphilis?",
        "sampleQueries": [
          "Does he need an LP?",
          "What are the CSF criteria for neurosyphilis?",
          "What is the treatment?"
        ],
        "responses": {
          "lp|lumbar|puncture|csf": {
            "content": "**Lumbar Puncture Decision â€” CDC 2021 Guidelines**\n\nPerform LP if ANY of the following:\n\n1. **Neurologic symptoms** (confusion, vision changes, headache)\n2. **Ocular symptoms** (uveitis, optic neuritis, vision loss)\n3. **Otologic symptoms** (hearing loss, tinnitus, vertigo)\n4. **Treatment failure** (rising titers after appropriate therapy)\n\n**This patient:** Has confusion + vision changes = **LP indicated**\n\n**CSF Studies to Send:**\nâ€¢ CSF-VDRL (specific, but insensitive)\nâ€¢ CSF FTA-ABS/TP-PA (highly sensitive)\nâ€¢ CSF cell count and protein\nâ€¢ CSF glucose",
            "sources": ["CDC 2021 STI Treatment Guidelines"]
          },
          "treatment|therapy|penicillin": {
            "content": "**Neurosyphilis Treatment â€” CDC 2021**\n\n**Aqueous Crystalline Penicillin G**\nâ€¢ 18-24 million units IV daily\nâ€¢ Given as 3-4 million units IV q4h OR continuous infusion\nâ€¢ Duration: **10-14 days**\n\n**Alternative (if penicillin allergy):**\nâ€¢ Desensitization to penicillin (preferred)\nâ€¢ OR Ceftriaxone 2g IV daily x 10-14 days (limited data)\n\n**Follow-up:**\nâ€¢ Recheck CSF at 6 months\nâ€¢ CSF-VDRL should decrease or be nonreactive",
            "sources": ["CDC 2021 STI Treatment Guidelines"]
          },
          "ocular|eye|vision|uveitis": {
            "content": "**Ocular Syphilis Considerations**\n\nOcular syphilis is a form of neurosyphilis â€” **treat as CNS disease**\n\n**Key Points:**\nâ€¢ Can affect any ocular structure (uveitis, optic neuritis, retinitis)\nâ€¢ May occur at any stage of infection\nâ€¢ LP recommended even without other neurologic symptoms\nâ€¢ Urgent ophthalmology consult\n\n**Treatment:** Same as neurosyphilis (IV penicillin G)",
            "sources": ["CDC 2021 STI Treatment Guidelines"]
          },
          "criteria|diagnosis|positive": {
            "content": "**Neurosyphilis Diagnostic Criteria**\n\nDefinite neurosyphilis requires:\n\n1. **Reactive CSF-VDRL** (specific, but insensitive ~30-70%)\n   - OR reactive CSF FTA-ABS with elevated CSF WBC/protein\n\n2. **Elevated CSF WBC** (>5 cells/Î¼L)\n\n3. **Elevated CSF protein** (>45 mg/dL)\n\n**Note:** CSF FTA-ABS is highly sensitive (~95%) but less specific â€” treponemal antibodies may persist after treatment.",
            "sources": ["CDC 2021 STI Treatment Guidelines"]
          },
          "default": {
            "content": "Based on this case of suspected neurosyphilis with neurologic symptoms, I recommend:\n\n1. **Perform LP** â€” indicated due to confusion and vision changes\n2. **Send CSF studies:** VDRL, FTA-ABS, cell count, protein, glucose\n3. **Start empiric IV penicillin G** 18-24 million units daily x 10-14 days\n4. **Ophthalmology consult** for vision changes\n5. **HIV testing** â€” concurrent HIV infection affects management\n\nWould you like details on CSF interpretation or treatment protocols?",
            "sources": ["CDC 2021 STI Treatment Guidelines"]
          }
        }
      },
      {
        "id": "pe-treatment",
        "title": "PE Risk Stratification",
        "description": "Hemodynamically stable patient with confirmed pulmonary embolism",
        "patientInfo": {
          "age": 67,
          "sex": "Female",
          "chiefComplaint": "Dyspnea and chest pain",
          "vitals": {
            "bp": "118/76",
            "hr": 108,
            "rr": 22,
            "spo2": 92,
            "temp": 37.1
          },
          "history": ["Recent hip surgery (2 weeks ago)", "CTPA confirmed submassive PE", "No hypotension"]
        },
        "openingMessage": "67yo female with submassive PE confirmed on CTPA. Hemodynamically stable currently. Key decision: risk stratification and whether to pursue systemic thrombolysis vs anticoagulation alone.",
        "sampleQueries": [
          "Is she high risk?",
          "Should I give tPA?",
          "What are the PESI criteria?"
        ],
        "responses": {
          "risk|pesi|spesi|score": {
            "content": "**Pulmonary Embolism Severity Index (PESI)**\n\n| Factor | Points |\n|--------|--------|\n| Age (years) | +1/year |\n| Male sex | +10 |\n| Cancer | +30 |\n| Heart failure | +20 |\n| Chronic lung disease | +20 |\n| HR >110 | +20 |\n| SBP <100 | +30 |\n| RR >30 | +20 |\n| Temp <36Â°C | +20 |\n| Altered mental status | +60 |\n| SpO2 <90% | +20 |\n\n**This patient:** Age 67 + HR 108 + SpO2 92% = **â‰¥67 points (Class III-IV)**\n\n**sPESI simplified:** Age>80, cancer, CHF, CLD, HR>110, SBP<100, SpO2<90% = **â‰¥1 point = higher risk**",
            "sources": ["ESC 2019 Guidelines", "Aujesky et al."]
          },
          "tpa|thrombolysis|lysis|systemic": {
            "content": "**Thrombolysis in Submassive PE â€” Risk Stratification**\n\n**Absolute indications (massive PE):**\nâ€¢ Sustained hypotension (SBP <90 or drop â‰¥40 for >15 min)\nâ€¢ Cardiogenic shock\n\n**Submassive PE â€” Consider thrombolysis if:**\nâ€¢ RV dysfunction on echo/CT + elevated troponin/BDNP\nâ€¢ Clinical deterioration despite anticoagulation\nâ€¢ High PESI/sPESI score\n\n**This patient:** Submassive, hemodynamically stable â†’\n**Start anticoagulation** (heparin infusion or DOAC)\n**Monitor closely** for deterioration\n\n**Dell Seton protocol:** Systemic tPA only if massive PE or clinical decompensation.",
            "sources": ["ESC 2019 Guidelines", "Dell Seton PE Protocol"]
          },
          "anticoagulation|heparin|apixaban|rivaroxaban|doac": {
            "content": "**PE Anticoagulation Options**\n\n**Parenteral (initial):**\nâ€¢ Unfractionated heparin â€” preferred if thrombolysis being considered\nâ€¢ LMWH (enoxaparin) â€” if no anticipated procedures\n\n**Oral (maintenance):**\nâ€¢ Apixaban 10mg BID x 7 days, then 5mg BID\nâ€¢ Rivaroxaban 15mg BID x 21 days, then 20mg daily\nâ€¢ DOACs preferred for hemodynamically stable patients\n\n**Duration:**\nâ€¢ Provoked PE (surgery): 3 months\nâ€¢ Unprovoked PE: Consider extended therapy\n\n**Contraindications to DOACs:**\nâ€¢ Active bleeding, severe renal impairment, antiphospholipid syndrome",
            "sources": ["CHEST 2021", "ESC 2019 Guidelines"]
          },
          "rv|right|ventricle|strain|echo": {
            "content": "**RV Dysfunction in PE**\n\n**Echo findings:**\nâ€¢ RV dilation (RV/LV ratio >0.9 or >1.0)\nâ€¢ Septal flattening (D-sign)\nâ€¢ McConnell's sign (RV free wall akinesis with apical sparing)\nâ€¢ TR with elevated RVSP\n\n**CT findings:**\nâ€¢ RV/LV diameter ratio >0.9\nâ€¢ Septal bowing toward LV\n\n**Significance:** RV dysfunction indicates hemodynamic compromise and is associated with increased mortality. Consider escalation of care.",
            "sources": ["ESC 2019 Guidelines"]
          },
          "default": {
            "content": "This 67yo with confirmed submassive PE requires:\n\n1. **Immediate anticoagulation** â€” UFH infusion if considering thrombolysis, otherwise LMWH or DOAC\n2. **Risk stratification** â€” PESI score, RV assessment\n3. **Admission** â€” telemetry for monitoring\n4. **Contraindications check** â€” bleeding risk, recent surgery\n\n**Key decision:** Systemic thrombolysis NOT indicated currently (hemodynamically stable). Reserve for massive PE or clinical deterioration.\n\nWould you like help with anticoagulation dosing or monitoring parameters?",
            "sources": ["ESC 2019 Guidelines", "Dell Seton PE Protocol"]
          }
        }
      },
      {
        "id": "pneumothorax",
        "title": "Pneumothorax POCUS",
        "description": "Traumatic pneumothorax evaluation with point-of-care ultrasound",
        "patientInfo": {
          "age": 28,
          "sex": "Male",
          "chiefComplaint": "Chest pain after MVC",
          "vitals": {
            "bp": "132/84",
            "hr": 96,
            "rr": 20,
            "spo2": 97,
            "temp": 36.8
          },
          "history": ["MVC with steering wheel impact", "Right chest wall tenderness", "Decreased breath sounds right"]
        },
        "openingMessage": "28yo male s/p MVC with right chest trauma. Decreased breath sounds on the right. Bedside ultrasound shows absent lung sliding and a lung point. This is a traumatic pneumothorax.",
        "sampleQueries": [
          "Do I need a chest tube?",
          "How big is it?",
          "Can I observe?"
        ],
        "responses": {
          "tube|chest|thoracostomy|drain": {
            "content": "**Chest Tube Indications â€” Traumatic Pneumothorax**\n\n**Absolute indications:**\nâ€¢ Respiratory distress or compromise\nâ€¢ Hemodynamic instability\nâ€¢ Tension physiology\nâ€¢ Progressive enlargement on imaging\n\n**Relative indications (OBS vs TUBE):**\nâ€¢ Size >2-3 cm at apex\nâ€¢ Positive pressure ventilation required\nâ€¢ Need for air transport\nâ€¢ Patient unreliable for follow-up\n\n**This patient:** Small pneumothorax on POCUS, hemodynamically stable, not on ventilator â†’ **May observe** with serial exams.\n\n**Observation criteria:**\nâ€¢ Admit 12-24h for monitoring\nâ€¢ Supplemental O2 (promotes reabsorption)\nâ€¢ Repeat CXR in 6-12 hours\nâ€¢ Immediate intervention if deterioration",
            "sources": ["ATLS 10th Edition", "EAST Guidelines"]
          },
          "size|measure|cm|measurement": {
            "content": "**Pneumothorax Size Estimation**\n\n**POCUS estimation:**\nâ€¢ Small: <2 cm interpleural distance at apex\nâ€¢ Large: >2 cm interpleural distance\n\n**Supine CXR (Collins method):**\nâ€¢ Approximate size = 4.2 + (4.7 Ã— A + B + C)\n  - A = interpleural distance at apex\n  - B = at mid-clavicular line\n  - C = at base\n\n**CT (most accurate):\nâ€¢ Measures actual volume\n\n**Clinical significance:**\nâ€¢ <2 cm (approx 15%): Often observe\nâ€¢ >2 cm or clinical symptoms: Consider drainage",
            "sources": ["EAST Guidelines"]
          },
          "observe|observation|watch|wait": {
            "content": "**Observation Criteria for Traumatic Pneumothorax**\n\n**Candidates for observation:**\nâœ“ Small pneumothorax (<2 cm or <15%)\nâœ“ Hemodynamically stable\nâœ“ No respiratory distress\nâœ“ Not requiring positive pressure ventilation\nâœ“ Reliable patient with close follow-up\n\n**Observation protocol:**\nâ€¢ Admit for monitoring (12-24 hours)\nâ€¢ High-flow O2 (promotes nitrogen washout)\nâ€¢ Serial physical exams\nâ€¢ Repeat CXR in 6-12 hours\n\n**Stop points for observation:**\nâœ— Clinical deterioration\nâœ— PTX enlargement on repeat imaging\nâœ— Need for positive pressure ventilation\nâœ— Development of hemothorax",
            "sources": ["EAST Guidelines"]
          },
          "poCUS|ultrasound|lung|sliding": {
            "content": "**POCUS for Pneumothorax â€” Key Findings**\n\n**Normal lung:**\nâ€¢ Lung sliding (seashore sign on M-mode)\nâ€¢ Comet tail artifacts (B-lines)\n\n**Pneumothorax:**\nâ€¢ **Absent lung sliding** â€” most sensitive\nâ€¢ **Stratosphere sign** on M-mode (barcode sign)\nâ€¢ **Lung point** â€” pathognomonic (100% specific)\nâ€¢ Absent B-lines\n\n**Extended FAST views:**\nâ€¢ Anterior 2nd-4th intercostal spaces (most sensitive for anterior PTX)\nâ€¢ Include lateral chest wall for complete evaluation\n\n**Limitations:**\nâ€¢ Subcutaneous emphysema obscures view\nâ€¢ Lateral/small PTX may be missed anteriorly\nâ€¢ Operator dependent",
            "sources": ["ATLS 10th Edition", "ACEP POCUS Guidelines"]
          },
          "default": {
            "content": "For this traumatic pneumothorax on POCUS:\n\n1. **Confirm findings** â€” Absent sliding + lung point = definite PTX\n2. **Assess size** â€” POCUS limited for size, get CXR/CT if clinical impact uncertain\n3. **Clinical status** â€” Stable vitals, no distress â†’ observation likely appropriate\n4. **High-flow O2** â€” Promotes reabsorption\n5. **Monitor** â€” Serial exams, repeat imaging in 6-12 hours\n\n**Tube thoracostomy** indicated if: respiratory distress, enlargement, need for PPV, or hemothorax.\n\nWant specific guidance on chest tube size or insertion site?",
            "sources": ["ATLS 10th Edition", "EAST Guidelines"]
          }
        }
      },
      {
        "id": "echo-views",
        "title": "Basic Echo Views",
        "description": "Point-of-care echocardiography for cardiac assessment",
        "patientInfo": {
          "age": 55,
          "sex": "Male",
          "chiefComplaint": "Chest pain and hypotension",
          "vitals": {
            "bp": "88/56",
            "hr": 112,
            "rr": 24,
            "spo2": 94,
            "temp": 36.9
          },
          "history": ["Acute chest pain", "Hypotension", "JVD present"]
        },
        "openingMessage": "55yo male with chest pain and hypotension (88/56). JVD present. You need to perform a bedside echo to assess for pericardial effusion, RV dilation, and global LV function.",
        "sampleQueries": [
          "What are the basic views?",
          "How do I see the effusion?",
          "What is RV dilation?"
        ],
        "responses": {
          "views|windows|basic|standard": {
            "content": "**5 Essential POCUS Echo Views**\n\n**1. Parasternal Long Axis (PLAX)**\nâ€¢ Probe: 3rd-4th LICS, left sternal border\nâ€¢ Indicator to right shoulder\nâ€¢ Shows: LV, LA, MV, AV, RVOT, pericardium\n\n**2. Parasternal Short Axis (PSAX)**\nâ€¢ Rotate 90Â° from PLAX\nâ€¢ Multiple levels: MV, papillary muscles, apex\nâ€¢ Shows: LV function (circular), septal motion\n\n**3. Apical 4-Chamber (A4C)**\nâ€¢ Probe: cardiac apex (5th ICS, MCL)\nâ€¢ Indicator to left shoulder\nâ€¢ Shows: All 4 chambers, AV valves, pericardium\n\n**4. Subcostal 4-Chamber**\nâ€¢ Probe: subxiphoid, flat orientation\nâ€¢ Indicator to left\nâ€¢ Shows: All 4 chambers, IVC, pericardium\n\n**5. IVC View**\nâ€¢ From subcostal, rotate to long axis of IVC\nâ€¢ Shows: IVC size and collapsibility",
            "sources": ["ACEP POCUS Guidelines", "ASE Guidelines"]
          },
          "effusion|tamponade|pericardial": {
            "content": "**Pericardial Effusion on POCUS**\n\n**Appearance:**\nâ€¢ Anechoic (black) stripe surrounding heart\nâ€¢ Usually most prominent dependent (posterior/inferior)\n\n**Quantification:**\nâ€¢ Small: <1 cm\nâ€¢ Moderate: 1-2 cm\nâ€¢ Large: >2 cm\n\n**Tamponade findings:**\nâ€¢ RA collapse (systole) â€” earliest\nâ€¢ RV collapse (diastole) â€” more specific\nâ€¢ IVC plethora (dilated, <50% collapsible)\nâ€¢ Swinging heart (large effusions)\n\n**Best views:**\nâ€¢ Subcostal (most dependent, often largest)\nâ€¢ PLAX (posterior effusion)\nâ€¢ A4C (inferior/lateral effusion)",
            "sources": ["ACEP POCUS Guidelines"]
          },
          "rv|right|ventricle|dilation|strain": {
            "content": "**RV Assessment on POCUS**\n\n**Normal RV:**\nâ€¢ Smaller than LV (RV:LV ratio <0.6)\nâ€¢ Crescent-shaped in PSAX\nâ€¢ Free wall thickness <5mm\n\n**RV Dilation (acute pressure overload):**\nâ€¢ RV:LV ratio >1.0 (A4C or PSAX)\nâ€¢ Septal flattening (D-sign in PSAX)\nâ€¢ McConnell's sign: RV free wall akinesis with apical sparing\n\n**Common causes of acute RV dilation:**\nâ€¢ Massive/submassive PE (most common in ED)\nâ€¢ RV infarct (inferior MI with ST elevation)\n\n**Best views:**\nâ€¢ A4C (RV:LV size comparison)\nâ€¢ PSAX (septal motion, D-sign)",
            "sources": ["ACEP POCUS Guidelines", "ESC Echo Guidelines"]
          },
          "lv|left|ventricle|function|ef": {
            "content": "**LV Function Assessment**\n\n**Qualitative (eyeball method):**\nâ€¢ Hyperdynamic: Endocardial surfaces nearly touch\nâ€¢ Normal: EF 50-70%, good wall motion\nâ€¢ Reduced: EF 30-50%, hypokinesis\nâ€¢ Severely reduced: EF <30%, minimal contraction\n\n**Quantitative estimates:**\nâ€¢ Fractional shortening: (LVEDD - LVESD)/LVEDD (normal 25-45%)\nâ€¢ Visual EF estimation (practice required)\n\n**Wall motion abnormalities:**\nâ€¢ Anterior/septal: LAD territory\nâ€¢ Inferior: RCA territory\nâ€¢ Lateral: LCx territory\n\n**Best views:**\nâ€¢ PLAX (anterior septum, posterior wall)\nâ€¢ PSAX (all segments at different levels)\nâ€¢ A4C (lateral wall, apex)",
            "sources": ["ACEP POCUS Guidelines", "ASE Guidelines"]
          },
          "default": {
            "content": "For this hypotensive patient with chest pain:\n\n1. **Start with subcostal view** â€” best for pericardial effusion (patient supine, pain allowing)\n2. **Check for effusion/tamponade** â€” anechoic stripe, RA/RV collapse\n3. **Assess RV size** â€” PE can cause acute RV dilation\n4. **Evaluate LV function** â€” is this cardiogenic shock?\n5. **IVC for volume status** â€” dilated, non-collapsible = high CVP\n\n**Differential based on echo findings:**\nâ€¢ Effusion with tamponade â†’ Pericardiocentesis\nâ€¢ RV dilation with septal shift â†’ Massive PE\nâ€¢ Severe LV dysfunction â†’ Cardiogenic shock\n\nNeed help with a specific view or finding?",
            "sources": ["ACEP POCUS Guidelines"]
          }
        }
      }
    ]
  },

  "trustBadges": [
    {
      "icon": "âœ“",
      "title": "Clinical Decision Support",
      "description": "Evidence-based algorithms aligned with current guidelines"
    },
    {
      "icon": "âœŽ",
      "title": "Peer-Reviewed Content",
      "description": "All clinical content reviewed by board-certified physicians"
    },
    {
      "icon": "ðŸ”’",
      "title": "HIPAA Compliant",
      "description": "Enterprise-grade security and privacy protection"
    },
    {
      "icon": "âš•",
      "title": "Built by Physicians",
      "description": "Designed by clinicians who understand the workflow"
    }
  ],

  "seo": {
    "title": "MedKitt â€” Clinical Consults, Solved",
    "description": "Evidence-based clinical decision support for healthcare professionals. Guided consults built on current evidence, accessible in 60 seconds.",
    "keywords": "clinical decision support, emergency medicine, medical consults, healthcare AI, physician tools"
  }
}
